Gustavo Lorente Email

Director . Calcilytix Therapeutics

Current Roles

Employees:
15
Revenue:
$2.3M
About
Calcilytix Therapeutics, an affiliate of BridgeBio Pharma, is a clinical-stage biopharmaceutical company focused on developing a targeted therapy for disorders of calcium homeostasis. Our product candidate, encaleret, is an investigational orally-administered small molecule designed to specifically inhibit the calcium-sensing receptor, hypothesized to restore normal serum calcium and lower urine calcium.
Calcilytix Therapeutics Address

San Francisco, CA
United States
Calcilytix Therapeutics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.